Answers are grounded in this paper and cite their sources.
Background: The National Melanoma Registry of Serbia, part of the European Melanoma Registry, includes 2,791 patients registered between 2017 and August 2025. Adjuvant treatment for stage III adjuvant disease was reimbursed in March 2024. Data on outcomes in patients with stage I-III disease and initial assessment of outcomes in patients with/without adjuvant treatment in stage III were analyzed.
No takes yet. Share an insight, caveat, or question.
Pavlica et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: